COGNITION THERAPEUTICS INC (CGTX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.75

From 52W high−60.25%

Volume571198.00

Market cap$69.17M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.75

From 52W high

−60.25%

Volume

571198.00

Market cap

$69.17M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

P/E (TTM)

—

RSI (14)

23.3

MomentumView details →

1D Return

−0.33%

YTD Return

−45.58%

SummaryUpdated Jun 1, 2026

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company went public in October 2021 and focuses on developing small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Cognition Therapeutics is currently advancing multiple clinical trials for its lead drug candidate across several neurodegenerative conditions, with significant backing from National Institutes of Health grants totaling over $170 million in non-dilutive funding.

Ask drillr about COGNITION THERAPEUTICS INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−50.80%

ROA (TTM)

−43.13%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+71.34%

FCF YoY

+42.40%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+62.35%

EBITDA YoY

+49.54%

MomentumView details →

1D Return

−0.33%

YTD Return

−45.58%

1Y Return

−59.85%

RSI (14)

23.3

vs 50D SMA

−23.85%

vs 200D SMA

−33.12%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

7.03x

Quick Ratio

7.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

36.84%

Beats (12Q)

9/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

33.61%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−16.77M

Op. CF (TTM)

−17.68M

Next earningsNov 5, 2026 →

Latest newsMore news →

COGNITION THERAPEUTICS INC announced the issuance of a composition-of-matter patent extending protection for zervimesine (CT1812) through 2045.7d ago

Cognition Therapeutics scheduled a Type C meeting with the FDA's Division of Neurology for October 20 to align on endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies.21d ago

Similar companies

Cardiff Oncology, Inc.CRDF MediciNova, Inc.MNOV Heron Therapeutics, Inc.HRTX Aptorum Group LimitedAPM Telomir Pharmaceuticals, Inc. Common StockTELO PDS Biotechnology CorporationPDSB Find similar companies →

Latest newsMore news →

COGNITION THERAPEUTICS INC announced the issuance of a composition-of-matter patent extending protection for zervimesine (CT1812) through 2045.7d ago Cognition Therapeutics scheduled a Type C meeting with the FDA's Division of Neurology for October 20 to align on endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies.21d ago Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.74d ago